

April 1, 2022  
Announcement no. 6

## Managers' transactions

In connection with the completion of BioPorto A/S' rights issue as described in company announcement no. 4, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely related with them.

<b>1. Details of the person discharging managerial responsibilities/person closely associated</b>	
a) Name	Christopher James Lindop
<b>2. Reason for the notification</b>	
a) Position/status	Chairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendment	Initial notification
<b>3. Details of the issuer</b>	
a) Name	BioPorto A/S
b) LEI	5299004SWFL5JAN4W830
<b>4. Details of the transaction(s)</b>	
a) Description of the financial instrument, type of instrument	Shares
Identification code	ISIN code DK0061685906 to be merged with permanent ISIN code DKDK0011048619, expectedly no later than on 5 April 2022
b) Nature of the transaction	Purchase (exercise of subscription rights in connection with rights issue)
c) Price(s) and volume(s)	Price: DKK 1.5, Volume: 111,621
d) Aggregated information	N/A
- Aggregated volume	
- Aggregated price	
e) Date of the transaction	2022-04-01 5:00 a.m. UTC (7:00 a.m. CEST)
f) Place of the transaction	Nasdaq Copenhagen A/S, XCSE

<b>1. Details of the person discharging managerial responsibilities/person closely associated</b>	
a) Name	Ejendomsselskabet Jano ApS
<b>2. Reason for the notification</b>	
a) Position/status	Closely associated person to Jan Leth Christensen, member of the Board of Directors of BioPorto A/S
b) Initial notification/amendment	Initial notification
<b>3. Details of the issuer</b>	
a) Name	BioPorto A/S
b) LEI	5299004SWFL5JAN4W830
<b>4. Details of the transaction(s)</b>	
a) Description of the financial instrument, type of instrument	Shares
Identification code	ISIN code DK0061685906 to be merged with permanent ISIN code DKDK0011048619, expectedly no later than on 5 April 2022
b) Nature of the transaction	Purchase (exercise of subscription rights in connection with rights issue)
c) Price(s) and volume(s)	Price: DKK 1.5, Volume: 8,042,433
d) Aggregated information	N/A
<ul style="list-style-type: none"> <li>- Aggregated volume</li> <li>- Aggregated price</li> </ul>	
e) Date of the transaction	2022-04-01 5:00 a.m. UTC (7:00 a.m. CEST)
f) Place of the transaction	Nasdaq Copenhagen A/S, XCSE

***For further information, please contact:***

Tim Eriksen, Investor Relations,  
Telephone +45 61 88 77 79, e-mail: [investor@bioporto.com](mailto:investor@bioporto.com)

***About BioPorto***

*BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers - tools designed to help clinicians make changes in patient management. BioPorto uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and*



*compelling products that focus on conditions where there is significant unmet medical need, and where BioPorto's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.*

*BioPorto's flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies.*

*BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. More information is available at [www.bioporto.com](http://www.bioporto.com).*